Every year, millions of women around the world are diagnosed with breast cancer. It is not only the most common cancer among women, but also one of the deadliest when not detected early. According to the World Health Organization, more than 2.3 million women are diagnosed with breast cancer annually, and approximately 700,000 women lose their lives to the disease. Alarmingly, many of these deaths are preventable through earlier diagnosis.

Early detection can increase breast cancer treatment success rates up to 90%. However, the current diagnostic process requires time, expertise, and meticulous attention. Overburdened healthcare systems and the manual interpretation of imaging results often lead to delays and diagnostic errors. This is where artificial intelligence presents a powerful opportunity.

Mamosis is a health tech spin-off of Pera Soft, is addressing this challenge with an AI-powered solution focused on early cancer detection. Based in London, Mamosis analyzes mammography images in just 5 seconds to identify cancerous tissues. Its AI module is continuously improving and currently achieves accuracy rates above 90%, marking a true transformation in healthcare—where traditional diagnostics can take days.

As publicly shared, Mamosis was born out of an academic idea developed by Pera Soft and evolved into a startup. With a clear mission to support healthcare professionals in clinical decision-making, Mamosis aims to make diagnoses faster and more reliable.

The platform is highly accessible: it integrates seamlessly with existing PACS systems in hospitals, eliminating the need for costly infrastructure investments. Web and mobile access also allow physicians to review patient reports remotely, even outside hospital settings.

Pera Soft’s co-founder, Oguzhan Cevik, emphasizes that high-quality, accurate data is critical to the success of AI systems. He highlights that, especially in sensitive sectors like healthcare, protecting personal and medical data is not only a legal obligation but also an ethical responsibility. Cevik notes that obtaining high-quality datasets remains one of the greatest challenges in disease detection—and that Mamosis is overcoming this challenge with impactful solutions.

What’s Next for Mamosis?

In the short term, the goal is to expand into more hospitals across Europe, provide training for healthcare professionals, and further improve diagnostic accuracy. In the long term, Mamosis aims to become a globally recognized diagnostic tool and contribute to health equity, especially in developing countries.

What Does Mamosis Offer?

• AI-powered image analysis: Results in just 5 seconds
• Accuracy rate: 90%+, with a system that continues to improve
• Accessibility: PACS-compatible, web & mobile accessible

As early cancer detection enters an exciting new era, Mamosis opens the door to a future where patient outcomes are improved and healthcare systems become more efficient.